XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Collaborative Arrangements and Licensing Agreements (Tables)
9 Months Ended
Sep. 30, 2022
Biogen Collaborations [Member]  
Collaborative Arrangements and Licensing Agreements [Abstract]  
Revenue from Collaborative Relationship

During the three and nine months ended September 30, 2022 and 2021, we earned the following revenue from our relationship with Biogen (in millions, except percentage amounts):

 
Three Months Ended
September 30,
   
Nine Months Ended
September 30,
 
   
2022
   
2021
   
2022
   
2021
 
SPINRAZA royalties (commercial revenue)
 
$
61.6
   
$
66.6
   
$
175.1
   
$
198.7
 
R&D revenue
   
27.4
     
17.4
     
84.6
     
63.4
 
Total revenue from our relationship with Biogen
 
$
89.0
   
$
84.0
   
$
259.7
   
$
262.1
 
Percentage of total revenue
   
56
%
   
63
%
   
60
%
   
71
%
Roche Collaborations [Member]  
Collaborative Arrangements and Licensing Agreements [Abstract]  
Revenue from Collaborative Relationship

During the three and nine months ended September 30, 2022 and 2021, we earned the following revenue from our relationship with Roche (in millions, except percentage amounts):

   
Three Months Ended
September 30,
   
Nine Months Ended
September 30,
 
   
2022
   
2021
   
2022
   
2021
 
R&D revenue
 
$
41.5
   
$
3.9
   
$
65.4
   
$
11.4
 
Percentage of total revenue
   
26
%
   
3
%
   
15
%
   
3
%